Sanofi’s Troujeo beats insulin degludec in head-to-head study in type 2 diabetes
pharmafile | September 19, 2019 | News story | Research and Development | Sanofi, Troujeo, diabetes, insulin degludec, pharma
Sanofi took the opportunity at the 55th annual European Association for the Study of Diabetes to present new data from the first randomised control study directly comparing its Toujeo product with insulin degludec (iDeg) in patients starting treatment with insulin for the first time to manage their type 2 diabetes.
In adult patients with type 2 diabetes and moderate-to-severe kidney impairment, the results of the study showed that Toujeo produced a 0.43% greater reduction in average blood sugar in patients with moderate-to-severe renal impairment throughout the 24-week study period compared to iDeg, with “similar rates of low blood sugar risk”.
Additionally, the same analysis revealed that a similar level of blood sugar control was observed in patients with normal kidney function from both treatments with lower rates of blood sugar.
“In patients with moderate-severe renal impairment, whose diabetes is often complex to manage, Gla-300 appears to confer glycaemic advantages versus IDeg, without compromising on hypoglycaemia, warranting further investigation,” commented Dr Martin Haluzik, Deputy Director, Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, and an investigator of the study. “These results are consistent with another exploratory analysis from BRIGHT, in which Gla-300 greater reduction in blood sugar and similar rates of hypoglycaemia were seen when compared to iDeg in people aged 70 years or older.”
Matt Fellows
Related Content
Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition
The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) …
